Impact of Atosiban administration on live birth rates in patients undergoing frozen embryo transfer: a retrospective self-controlled study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20261596Keywords:
Atosiban, Frozen embryo transfer, Implantation failure, Live birth rate, Uterine contractility, IVFAbstract
Background: To evaluate the impact of Atosiban, an oxytocin receptor antagonist, on live birth rates (LBR) and other pregnancy outcomes in patients with a history of failed frozen embryo transfer (FET) cycles.
Methods: This was a retrospective, self-controlled study conducted at a single tertiary care center between January 2018 and December 2024. A cohort of 73 patients who had undergone at least one unsuccessful FET cycle (Cycle 1) without atosiban and a subsequent FET cycle with Atosiban administration (Cycle 2) were included. Each patient served as her own control. The primary outcome was the live birth rate. Secondary outcomes included biochemical pregnancy, clinical pregnancy, miscarriage, and implantation rates. Statistical analysis involved paired t-tests for continuous variables and Fisher's exact test for categorical outcomes.
Results: The administration of Atosiban in Cycle 2 was associated with a significant improvement in pregnancy outcomes. The live birth rate increased from 0% in Cycle 1 to 26.0% in Cycle 2 (p<0.001). Similarly, the clinical pregnancy rate rose from 2.7%-43.8% (p<0.001), and the biochemical pregnancy rate increased from 11.0%-65.8% (p<0.001). The implantation rate showed a non-significant increase from 50% in Cycle 1 to 55% in Cycle 2 (p=0.372).
Conclusions: In a self-controlled cohort of patients with previous FET failure, Atosiban administration at the time of embryo transfer was associated with a statistically and clinically significant increase in live birth rates. These findings support Atosiban as a valuable therapeutic option to improve implantation success in this challenging patient population.
References
Coughlan C, Ledger W, Wang Q, Liu F, Demirol A, Gurgan T, et al. Recurrent implantation failure: definition and management. Reprod Biomed Online. 2014;28(1):14-38.
Zhu L, Che HS, Xiao L, Li YP. Uterine peristalsis before embryo transfer affects the chance of clinical pregnancy in fresh and frozen-thawed embryo transfer cycles. Hum Reprod. 2014;29(6):1238-43.
Buddhabunyakan N, Sothornwit J, Seejorn K, Buppasiri P, Salang L. Effects of atosiban on uterine peristalsis following frozen embryo transfer: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2021;265:96-101.
Pierzynski P, Reinheimer TM, Kuczynski W. Oxytocin antagonists may improve infertility treatment. Fertil Steril. 2007;88(1):213.e19-22.
Cai H, Liu S, Chen L, Xie J, Yang C, Li W, et al. Effectiveness of atosiban in women with previous single implantation failure undergoing frozen-thawed blastocyst transfer: study protocol for a randomised controlled trial. BMJ Open. 2023;13(10):e076390.
Mishra V, Agarwal H, Goel S, Roy P, Choudhary S, Lamba S. A prospective case-control trial to evaluate and compare the efficacy and safety of atosiban versus placebo in in vitro fertilization–embryo transfer program. J Hum Reprod Sci. 2018;11(2):155-60.
Moraloglu O, Tonguc E, Var T, Zeyrek T, Batioglu S. Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF. Reprod Biomed Online. 2010;21(3):338-43.
Ng EHY, Li RHW, Chen L, Lan VT, Tuong HM, Quan S. A randomized double-blind comparison of atosiban in patients undergoing IVF treatment. Hum Reprod. 2014;29(12):2687-94.
Wu MH, Lin CW, Su PF, Lai EC, Sie FC, Mau YL, et al. Atosiban and pregnancy outcomes following in vitro fertilization treatment for infertile women requiring one, two, or more embryo transfer cycles: a longitudinal cohort study. Reprod Sci. 2020;27(3):853-9.
Yuan C, Song H, Fan L, Su S, Dong B. The effect of atosiban on patients with difficult embryo transfers undergoing in vitro fertilization–embryo transfer. Reprod Sci. 2019;26(12):1613-7.
Wang R, Huang H, Tan Y, Xia G. Efficacy of atosiban for repeated embryo implantation failure: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1161707.
Chou PY, Wu MH, Pan HA, Hung KH, Chang FM. Use of an oxytocin antagonist in in vitro fertilization–embryo transfer for women with repeated implantation failure: a retrospective study. Taiwan J Obstet Gynecol. 2011;50(2):136-40.
Lan VT, Khang VN, Nhu GH, Tuong HM. Atosiban improves implantation and pregnancy rates in patients with repeated implantation failure. Reprod Biomed Online. 2012;25(3):254-60.
Schwarze JE, Crosby J, Mackenna A. Atosiban improves the outcome of embryo transfer: a systematic review and meta-analysis of randomized and non-randomized trials. JBRA Assist Reprod. 2020;24(4):421-7.
Yang Y, Luo R, Qin S, Zhu W, Yang M, Zhu D, et al. The effect of atosiban on pregnancy outcomes in different FET cycles: a single-center matched retrospective cohort study. Front Endocrinol (Lausanne). 2025;16:1547694.
Huang QY, Rong MH, Lan AH, Lin XM, Lin XG, He RQ, et al. The impact of atosiban on pregnancy outcomes in women undergoing in vitro fertilization–embryo transfer: a meta-analysis. PLoS One. 2017;12(4):e0175501.
Downloads
Published
How to Cite
Issue
Section
